Novel CRTH2 antagonists: a review of patents from 2006 to 2009

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Novel CRTH2 antagonists: a review of patents from 2006 to 2009. / Ulven, Trond; Kostenis, Evi.

In: Expert Opinion on Therapeutic Patents, Vol. 20, No. 11, 01.11.2010, p. 1505-1530.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ulven, T & Kostenis, E 2010, 'Novel CRTH2 antagonists: a review of patents from 2006 to 2009', Expert Opinion on Therapeutic Patents, vol. 20, no. 11, pp. 1505-1530. https://doi.org/10.1517/13543776.2010.525506

APA

Ulven, T., & Kostenis, E. (2010). Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opinion on Therapeutic Patents, 20(11), 1505-1530. https://doi.org/10.1517/13543776.2010.525506

Vancouver

Ulven T, Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opinion on Therapeutic Patents. 2010 Nov 1;20(11):1505-1530. https://doi.org/10.1517/13543776.2010.525506

Author

Ulven, Trond ; Kostenis, Evi. / Novel CRTH2 antagonists: a review of patents from 2006 to 2009. In: Expert Opinion on Therapeutic Patents. 2010 ; Vol. 20, No. 11. pp. 1505-1530.

Bibtex

@article{9b7f64dc930446039ddb03f6209bc568,
title = "Novel CRTH2 antagonists: a review of patents from 2006 to 2009",
abstract = "The receptor CRTH2 (also known as DP₂) is an important mediator of the inflammatory effects of prostaglandin D₂ and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.",
author = "Trond Ulven and Evi Kostenis",
year = "2010",
month = nov,
day = "1",
doi = "10.1517/13543776.2010.525506",
language = "English",
volume = "20",
pages = "1505--1530",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Taylor & Francis",
number = "11",

}

RIS

TY - JOUR

T1 - Novel CRTH2 antagonists: a review of patents from 2006 to 2009

AU - Ulven, Trond

AU - Kostenis, Evi

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The receptor CRTH2 (also known as DP₂) is an important mediator of the inflammatory effects of prostaglandin D₂ and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.

AB - The receptor CRTH2 (also known as DP₂) is an important mediator of the inflammatory effects of prostaglandin D₂ and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.

U2 - 10.1517/13543776.2010.525506

DO - 10.1517/13543776.2010.525506

M3 - Journal article

VL - 20

SP - 1505

EP - 1530

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 11

ER -

ID: 189162560